Pharmacological options for treatment of hyperandrogenic disorders

P. Reismann, I. Likó, P. Igaz, A. Patócs, K. Rácz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.

Original languageEnglish
Pages (from-to)1113-1126
Number of pages14
JournalMini-Reviews in Medicinal Chemistry
Volume9
Issue number9
DOIs
Publication statusPublished - 2009

Fingerprint

Androgen Receptors
Pharmacology
Androgens
Oxidoreductases
Finasteride
Flutamide
Cyproterone Acetate
Androgen Antagonists
Spironolactone
Ketoconazole
Dihydrotestosterone
Polycystic Ovary Syndrome
Gonads
Gonadotropin-Releasing Hormone
Pharmaceutical Preparations
Testosterone
Transcription Factors
Therapeutics
Insulin
Ligands

Keywords

  • 5α-reductase inhibitors
  • Androgen excess
  • Androgen receptor antagonists
  • Antiandrogen therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Pharmacological options for treatment of hyperandrogenic disorders. / Reismann, P.; Likó, I.; Igaz, P.; Patócs, A.; Rácz, K.

In: Mini-Reviews in Medicinal Chemistry, Vol. 9, No. 9, 2009, p. 1113-1126.

Research output: Contribution to journalArticle

@article{98d7a6161f924e349561aa27ef4637ba,
title = "Pharmacological options for treatment of hyperandrogenic disorders",
abstract = "Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7{\%} in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.",
keywords = "5α-reductase inhibitors, Androgen excess, Androgen receptor antagonists, Antiandrogen therapy",
author = "P. Reismann and I. Lik{\'o} and P. Igaz and A. Pat{\'o}cs and K. R{\'a}cz",
year = "2009",
doi = "10.2174/138955709788922692",
language = "English",
volume = "9",
pages = "1113--1126",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Pharmacological options for treatment of hyperandrogenic disorders

AU - Reismann, P.

AU - Likó, I.

AU - Igaz, P.

AU - Patócs, A.

AU - Rácz, K.

PY - 2009

Y1 - 2009

N2 - Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.

AB - Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.

KW - 5α-reductase inhibitors

KW - Androgen excess

KW - Androgen receptor antagonists

KW - Antiandrogen therapy

UR - http://www.scopus.com/inward/record.url?scp=70349577619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349577619&partnerID=8YFLogxK

U2 - 10.2174/138955709788922692

DO - 10.2174/138955709788922692

M3 - Article

C2 - 19689407

AN - SCOPUS:70349577619

VL - 9

SP - 1113

EP - 1126

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 9

ER -